Importantly, downregulation of CPS1 leads to an increase in the levels of cyclic AMP (cAMP) and activation of protein kinase A (PKA)-cAMP response element-binding protein (CREB)/ATF1 axis, which compromises the anti-cancer effects of aspirin. This evidence concerns the gene ATF1 and cancer.